biostudies-literatureUnknown9(8)Larue M<h4>Abstract</h4>To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-world cohort study were performed. Participants were adults with primary ITP, transient response to corticosteroids with/without intravenous immunoglobulin, and a platelet count of ≤30 × 109/L (or ≤50 × 109/L with bleeding). Patients in the RCT were randomized in arm A (prednisone × 3 weeks + dapsone for 12 months) or arm B (prednisone alone). The observational study involved dapsone initiation at 100 mg/d with standard follow-up. The primary end point was the response rate (platelet count of >30 × 109/L and ≥2× baseline level) at 52 weeks, with the response rate at 24 weeks and adverse events as secondary end points. The RCT enrolled Blood advances1976-1983https://www.ebi.ac.uk/biostudies/studies/S-EPMC12018975biostudies-literatureEfficacy and safety of dapsone in adult primary immune thrombocytopenia.PMC12018975Larue MEbbo MDuong TARueter MBonnotte BLefrere FRoyer BBoutin ELanguille LViallard JFLambotte OMahevas MMoulis GMichel MAudia SGalicier LGodeau BCanoui-Poitrine FComont TPan-Petesch BTerriou LCheze SfalseEfficacy and safety of dapsone in adult primary immune thrombocytopenia.<h4>Abstract</h4>To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-world cohort study were performed. Participants were adults with primary ITP, transient response to corticosteroids with/without intravenous immunoglobulin, and a platelet count of ≤30 × 109/L (or ≤50 × 109/L with bleeding). Patients in the RCT were randomized in arm A (prednisone × 3 weeks + dapsone for 12 months) or arm B (prednisone alone). The observational study involved dapsone initiation at 100 mg/d with standard follow-up. The primary end point was the response rate (platelet count of >30 × 109/L and ≥2× baseline level) at 52 weeks, with the response rate at 24 weeks and adverse events as secondary end points. The RCT enrolled 2025-01-01T00:00:00Z2025 Apr2026-07-15T11:01:15.734Z2026-07-03T03:15:57.814ZS-EPMC120189753987452110.1182/bloodadvances.2024014939